Viking Therapeutics, Inc. (VKTX) declines more than market: Some information for investors
Viking Therapeutics (VKTX) experienced a decline of 1.48% in its stock price, underperforming the S&P 500's 0.23% gain on the day. The recent trading activity places VKTX shares at $77.89, with a year-to-date gain of over 113%. Investors are looking forward to the company's next earnings report, where analysts project a loss of $0.20 per share and revenue of $0, indicating a focus on pipeline development rather than immediate sales.
How New Oral VK2735 Obesity Data At Viking Therapeutics (VKTX) Has Changed Its Investment Story
Viking Therapeutics presented new data for its oral VK2735 obesity therapy, showing statistically significant and dose-dependent weight loss with a mild side-effect profile. This data strengthens the investment narrative around VK2735, suggesting it could become a significant product, although risks remain regarding Phase III timelines and competitive landscape. The company's forecasts project substantial revenue and earnings growth by 2029, with some analysts seeing considerable upside.
How New Oral VK2735 Obesity Data At Viking Therapeutics (VKTX) Has Changed Its Investment Story
Viking Therapeutics (VKTX) recently presented promising new Phase 2 data for its oral VK2735 obesity therapy, showing significant dose-dependent weight loss and a good safety profile. These results strengthen the case for starting Phase 3 oral trials, making VK2735 a potential parallel value driver alongside its injectable counterpart. While offering a strong upside potential based on analyst forecasts, the investment narrative is balanced by risks like rising R&D costs and dependence on VK2735's success.
Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026
Viking Therapeutics presented additional data from its Phase 2 VENTURE-Oral Dosing trial of VK2735 at the European Congress on Obesity (ECO) 2026. The oral tablet formulation of VK2735 achieved statistically significant, dose-dependent weight loss of up to 12.2% (26.6 lbs) at 13 weeks, with 97% of participants achieving ≥5% weight loss and 80% achieving ≥10% weight loss. The drug was well-tolerated, and Viking plans to initiate Phase 3 trials for the oral tablet later this year, aiming for it to be the first oral dual agonist of GLP-1 and GIP receptors on the market.
Earnings call transcript: Viking Therapeutics Q1 2026 sees widened net loss By Investing.com
Viking Therapeutics (VKTX) reported a significant net loss of $158.3 million in Q1 2026, widening by 247% year-over-year, primarily due to a 178% surge in R&D expenses for accelerated clinical development. The company missed EPS forecasts by 34.31%, leading to a 3.74% stock drop in after-hours trading. Despite this, Viking remains optimistic about its lead obesity program, VK2735, with ongoing Phase III trials and sufficient cash to fund operations through 2028.
VKTX stock slips premarket: A surprise weight loss drug beats Novo Nordisk in early animal tests
The article discusses how VKTX stock slipped premarket after an early animal test showed its weight loss drug outperformed Novo Nordisk's offerings. This indicates potential competition in the weight loss drug market, which could impact investor sentiment.
Should Viking’s VK2735 Obesity Data Debut in Europe Require Action From Viking Therapeutics (VKTX) Investors?
Viking Therapeutics (VKTX) is set to present data on its VK2735 obesity program at the European Congress on Obesity, including Phase 2 VENTURE-Oral efficacy and safety data and Phase 3 VANQUISH-1 trial details. While this highlights Viking's efforts to compete in the obesity treatment market, the company's investment narrative remains dependent on successful VK2735 development due to a lack of revenue and growing losses. Investors should note the significant cash burn and trial risks, despite some analysts projecting considerable revenue and earnings for VK2735 by 2029.
Should Viking’s VK2735 Obesity Data Debut in Europe Require Action From Viking Therapeutics (VKTX) Investors?
Viking Therapeutics (VKTX) will present data on its VK2735 obesity program at the 33rd European Congress on Obesity, including Phase 2 VENTURE-Oral efficacy and safety data and Phase 3 VANQUISH-1 trial design. This highlights Viking's strategy to compete in the GLP-1 and dual GLP-1/GIP obesity treatment market. The company’s continued financial losses despite promising drug development underscore the high stakes for the successful progression of VK2735.
Obesity drug pill data and Phase 3 trial details head to ECO 2026
Viking Therapeutics will be presenting two posters on its VK2735 obesity drug program at the European Congress on Obesity (ECO) in Istanbul from May 12-15, 2026. One poster will detail 13-week Phase 2 VENTURE-Oral efficacy and safety data, while the second will describe the Phase 3 VANQUISH-1 design and enrollment demographics for the subcutaneous formulation of VK2735. The presentations will highlight both the oral and subcutaneous formulations of VK2735, a dual GLP-1/GIP agonist for metabolic disorders.
Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026
Viking Therapeutics will present two posters at the 33rd European Congress on Obesity (ECO) in Istanbul, Türkiye, showcasing data from its VK2735 program. The presentations will highlight results from the Phase 2 VENTURE-Oral Dosing trial, focusing on efficacy and safety, as well as the design and enrollment demographics of the ongoing Phase 3 VANQUISH-1 study for subcutaneous VK2735. VK2735 is a dual agonist of GLP-1 and GIP receptors being developed for the treatment of metabolic disorders, including obesity, in both oral and subcutaneous formulations.
Why Viking Therapeutics (VKTX) Is Down 8.4% After Expanding VK2735 Phase 3 Obesity Program And Loss
Viking Therapeutics (VKTX) experienced an 8.4% stock drop after reporting a wider Q1 2026 net loss of US$158.33 million, driven by increased R&D spending. Despite the loss, the company fully enrolled its Phase 3 VANQUISH-1 and VANQUISH-2 obesity trials for VK2735 and plans to expand the program to include oral treatments, supported by a US$603 million cash position. The success of these trials is crucial for VKTX to convert research losses into product revenue, though analysts have varying revenue and earnings forecasts for 2029, with some predicting a significant upside.
Viking Therapeutics (VKTX) Is Down 8.5% After Wider Q1 Loss And VANQUISH-2 Enrollment Completion - Has The Bull Case Changed?
Viking Therapeutics (VKTX) reported a wider Q1 2026 net loss of US$158.33 million and completed patient enrollment in its Phase 3 VANQUISH-2 trial for obesity drug candidate VK2735. The article discusses how the company's investment narrative is heavily reliant on the success of VK2735 in trials, balancing the significant R&D costs against the potential for future revenue. While analysts project substantial revenue and earnings growth by 2029 if VK2735 succeeds, the increasing losses highlight the risks associated with the pre-revenue phase and the concentration on a single drug mechanism.
A Look At Viking Therapeutics (VKTX) Valuation As Phase 3 Obesity Program Reaches Key Enrollment Milestones
Viking Therapeutics (VKTX) has completed enrollment in its Phase 3 VANQUISH-1 and VANQUISH-2 trials for injectable VK2735 and plans an oral Phase 3 program, reflecting its deep dive into late-stage obesity drug development. Despite recent share price declines due to Q1 losses and increased R&D, the company's 5-year total shareholder return remains substantial. The stock is currently deemed 67.6% undervalued, with a fair value of $92.72 compared to its last closing price of $30, driven by projections of future revenue, margin expansion, and a high earnings multiple.
Viking Therapeutics Faces Timeline Risk—But Upside Could Be Huge
This article analyzes Sherwin-Williams' Q1 2026 earnings, which beat expectations despite a soft housing market and rising input costs. The company, a Dividend Aristocrat, faces valuation concerns with its P/E ratio higher than the market and its sector, but showcases a strong balance sheet. Its long-term compounding ability is highlighted, with potential for accelerated growth if mortgage rates decline.
Viking Therapeutics, Inc. $VKTX Shares Sold by Pictet Asset Management Holding SA
Pictet Asset Management Holding SA reduced its stake in Viking Therapeutics (NASDAQ:VKTX) by 37.1% during the fourth quarter, selling 443,573 shares and retaining 752,732 shares valued at $26.48 million. Despite Viking Therapeutics missing Q1 EPS expectations, analysts maintain a "Moderate Buy" rating with a consensus price target of $95.50, driven by progress in their Phase 3 clinical trials and a strong cash position. Company insiders have also been active, with one insider purchasing 4,475 shares in March.
Viking Therapeutics (VKTX) Is Down 8.5% After Wider Q1 Loss And VANQUISH-2 Enrollment Completion - Has The Bull Case Changed?
Viking Therapeutics (VKTX) reported a wider Q1 2026 net loss of US$158.33 million and a loss per share of US$1.37, causing its stock to drop 8.5%. Despite the increased losses, the company completed patient enrollment in its pivotal Phase 3 VANQUISH-2 trial for the obesity drug candidate VK2735, a key development that keeps the primary near-term catalyst intact. The article highlights the dependency of the company's investment narrative on successful Phase 3 outcomes for VK2735, with potential upside if efficacy and safety data are strong, but significant downside if results disappoint.
Viking Therapeutics 1Q 2026: Revenue $0 Net loss $(158.3M), EPS $(1.37) — 10-Q Summary
Viking Therapeutics reported its first-quarter 2026 results with no revenue and a significant increase in net loss to $(158.3M), or $(1.37) diluted loss per share, compared to the previous year. Despite the financial losses, the company highlighted substantial clinical progress, including advancing VK2735 to Phase 3 studies and securing manufacturing agreements, with cash reserves expected to fund operations through mid-2027.
VKTX: Viking Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas
Viking Therapeutics (VKTX) is planning to initiate a Phase 3 oral VK2735 trial for obesity in Q4 2026 and expects to release data from the VK2735 maintenance dosing study in Q3 2026. Despite fully enrolling subcutaneous VK2735 Phase 3 trials and advancing its oral formulation, the company reported a net loss of $158.3 million and increased R&D expenses for Q1 2026, with its cash position decreasing to $603 million.
Viking Therapeutics Q1 2026 Earnings Call Transcript
Viking Therapeutics provided an update on its Q1 2026 financial results and pipeline progress. The company announced the completion of enrollment for its Phase III VANQUISH-1 and VANQUISH-2 trials for subcutaneous VK2735 and plans to initiate a Phase III oral VK2735 program in Q4 2026. Despite a material increase in R&D expenses leading to a net loss of $158.3 million, Viking maintains a cash runway into 2028 and is advancing its novel amylin program, VK3019, to Phase I clinical trials.
Earnings Flash (VKTX) Viking Therapeutics Posts Q1 EPS -$1.37, Vs. FactSet Est of -$0.98
Viking Therapeutics (VKTX) reported a first-quarter loss of $1.37 per share, significantly missing the FactSet estimate of a $0.98 loss per share. This financial update indicates a larger-than-expected loss for the company during the quarter.
Viking Therapeutics net loss widens, cash position falls
Viking Therapeutics (VKTX) reported a significant widening of its GAAP EPS loss in Q1 to ($1.37) from ($0.41) year-over-year. This deterioration was primarily due to a nearly threefold increase in total operating expenses, reaching approximately $164.1 million. The biopharma company focuses on metabolic and endocrine disorders.
Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Viking Therapeutics announced its Q1 2026 financial results, highlighting significant progress in its VK2735 obesity programs, with Phase 3 subcutaneous trials fully enrolled and Phase 3 oral tablet trials expected to begin in Q4 2026. The company also filed an IND for its novel amylin agonist VK3019 and reported a strong quarter-end cash position of $603 million. Research and development expenses increased significantly due to ongoing clinical studies, resulting in a net loss of $158.3 million for the quarter.
What is Driving a Strong Bullish Sentiment Towards Viking Therapeutics (VKTX)
Viking Therapeutics Inc. (NASDAQ: VKTX) is generating strong bullish sentiment due to its advanced clinical trials for VK2735, a dual agonist for GLP-1 and GIP receptors. The company has completed patient recruitment for its Phase 3 VANQUISH-2 study and enrollment for the VANQUISH-1 trial, both investigating VK2735 for metabolic diseases and obesity. Additionally, Viking is conducting a Phase 1 trial for maintenance dosing strategies of VK2735, with results anticipated in Q3 2026, further highlighting its focus on developing treatments for obesity, fatty liver, and diabetes.
Viking Therapeutics (VKTX) Set to Release Q1 Earnings on April 2
Viking Therapeutics (VKTX) is scheduled to release its first-quarter earnings on April 29, 2026, with analysts anticipating an EPS of -$0.91. While the biotechnology company boasts strong financial strength, its profitability remains weak, leading to a GF Score™ of 41/100. This report, combined with mixed insider trading activity, suggests investors should approach VKTX with caution given its challenges in revenue generation and consistent losses.
Viking Therapeutics Inc expected to post a loss of $1.01 a share - Earnings Preview
Viking Therapeutics Inc (VKTX) is projected to report a loss of $1.01 per share. This information comes from a Refinitiv earnings preview.
Is Viking Therapeutics (VKTX) Still Attractive After Recent Share Price Swings?
This article analyzes Viking Therapeutics (VKTX) using Discounted Cash Flow (DCF) and Price-to-Book (P/B) ratio methods. Despite recent share price fluctuations, the DCF analysis suggests an 87.1% undervaluation compared to its intrinsic value of $255.20 per share. The P/B ratio also indicates undervaluation relative to its fair ratio, positioning VKTX as an attractive investment from a valuation perspective.
Viking Therapeutics Stock Price Target and Weight-Loss Drug Outlook - News and Statistics
Viking Therapeutics has a bullish one-year price target of $93.59, forecasting an over 170% increase despite recent stock underperformance. The company is well-positioned to challenge established weight-loss drug leaders Novo Nordisk and Eli Lilly with its dual-agonist drug VK2735, which is in phase 3 trials for an injectable form and phase 2 for a pill. This optimistic outlook is driven by the potential differentiation of VK2735 in the GLP-1 based weight-loss drug market.
Concurrent Investment Advisors LLC Grows Position in Viking Therapeutics, Inc. $VKTX
Concurrent Investment Advisors LLC significantly increased its stake in Viking Therapeutics (NASDAQ:VKTX) by 1,624% in the fourth quarter, now holding 281,052 shares valued at approximately $9.89 million. Despite the investment firm's increased position, Viking Therapeutics reported a Q4 EPS loss of ($1.38), missing consensus estimates. The stock currently holds a "Moderate Buy" consensus rating from analysts with an average target price of $94.22.
Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?
This article analyzes why Viking Therapeutics (VKTX) might be a good investment, focusing on the recent upgrades by Wall Street analysts and the company's strong "Strong Buy" consensus rating. It highlights the significant upside potential indicated by the average price target and recent positive revisions, suggesting a favorable outlook for the stock.
Raymond James reiterates Strong Buy on Viking Therapeutic stock By Investing.com
Raymond James has reaffirmed its "Strong Buy" rating and a $118.00 price target for Viking Therapeutic (NASDAQ:VKTX). The firm addressed investor interest in a recent pre-print study comparing tirzepatide and semaglutide, concluding that Viking Therapeutic's prospects remain neutral to positive despite the study's findings on lean body mass loss in GLP-1 agonists. This re-endorsement comes amid Viking Therapeutics' advancement of its VK2735 clinical trials and continued positive analyst sentiment.
Viking Therapeutics, Inc. (VKTX) exceeds market returns: Some facts to consider
This article analyzes Viking Therapeutics, Inc.'s (VKTX) stock performance, highlighting its significant outperformance compared to the market average and the Medical sector over the past year. It delves into key financial metrics such as price-to-earnings (P/E) ratio, price-to-book (P/B) ratio, and debt-to-equity (D/E) ratio to provide a comprehensive financial overview and potential investment considerations.
Viking Therapeutics, Inc. (VKTX) suffers a larger drop than the general market: Key insights
This article analyzes Viking Therapeutics, Inc.'s stock performance, noting its recent underperformance compared to the broader market. It would likely delve into factors contributing to the decline and provide key financial insights for investors.
Viking Therapeutics rises after Q4 updates on obesity therapy
Viking Therapeutics saw its shares rise following Q4 updates regarding its obesity therapy. Further details on the specific updates and their implications for the company's stock performance are not provided in this snippet.
Assessing Viking Therapeutics (VKTX) Valuation As Long Term Returns Contrast With Recent Share Price Moves
Viking Therapeutics (VKTX) is attracting attention due to recent share price movements, with long-term holders seeing significant returns despite short-term fluctuations. The company, which is still loss-making, is considered undervalued by some metrics, with a narrative suggesting a fair value of $92.72, primarily based on the potential of its GLP-1 and GIP co-agonist drug in development. However, another view highlights its rich valuation based on its Price-to-Book (P/B) ratio compared to the industry and peers, indicating potential upside limitations if expectations cool.
Viking Therapeutics (NASDAQ:VKTX) Stock Crosses Above 50 Day Moving Average - Here's What Happened
Viking Therapeutics (NASDAQ:VKTX) stock recently crossed above its 50-day moving average, trading at $34.25 with a volume of over 1.6 million shares. Despite analysts giving it a "Moderate Buy" rating and a consensus target price of $94.22, the company reported a missed Q4 EPS of ($1.38) against estimates of ($0.89), with expected continued losses for the current year. Insider Neil William Aubuchon also increased his stake by acquiring 4,475 shares.
Viking Therapeutics, Inc. (VKTX) exceeds market returns: Some facts to consider
This article from MSN discusses how Viking Therapeutics, Inc. (VKTX) has outperformed the broader market. It encourages readers to consider several key facts when evaluating the company's performance. The detailed content of the article is not provided, but the title suggests a focus on VKTX's market returns.
Viking Therapeutics to Release Q1 2026 Financial Results and Host Conference Call
Viking Therapeutics is scheduled to release its Q1 2026 financial results after market close on April 29, 2026, and will host a conference call on the same day at 4:30 p.m. ET to discuss these results and provide corporate updates. The company is actively progressing with its clinical trials, including Phase 3 for VK2735 for obesity and Phase 2 for VK2809 for non-alcoholic fatty liver disease, both showing promising early results that could significantly impact its market position. Analysts largely maintain a "Strong Buy" rating for VKTX, anticipating a substantial upside despite projected Q1 losses, based on the potential of its drug pipeline in the growing metabolic and endocrine disorder markets.
Viking Therapeutics schedules April 29 call for Q1 results, updates
Viking Therapeutics (NASDAQ: VKTX) has scheduled the release of its first-quarter 2026 financial results for after market close on Wednesday, April 29, 2026. This will be followed by a conference call at 4:30 p.m. ET to discuss the results and provide corporate updates. Investors can access a live webcast and a telephone replay of the call.
Viking Therapeutics to Report Financial Results for First Quarter 2026 on April 29, 2026
Viking Therapeutics, Inc. announced that it will release its financial results for the first quarter of 2026 after market close on Wednesday, April 29, 2026. The company will host a conference call at 4:30 p.m. Eastern Time on the same day to discuss the results and provide general corporate updates. A replay of the call will be available until May 6, 2026, and a webcast archive will also be accessible online for 30 days.
Viking Therapeutics to Report Financial Results for First Quarter 2026 on April 29, 2026
Viking Therapeutics, Inc. (NASDAQ: VKTX) has announced that it will release its financial results for the first quarter of 2026 after market close on Wednesday, April 29, 2026. The company will also host a conference call at 4:30 p.m. Eastern Time on the same day to discuss the results and provide general corporate updates. Viking Therapeutics is a clinical-stage biopharmaceutical company focusing on novel therapies for metabolic and endocrine disorders, with programs including VK2735 for obesity and VK2809 for NASH and NAFLD.
VKTX Q1'26 Earnings: revenue estimate is 0 USD
Viking Therapeutics, Inc. (VKTX) is scheduled to release its Q1'26 earnings on April 29th, with an expected revenue of $0 and an EPS of ($0.98). This report highlights key financial estimates for the upcoming announcement. Investors can find detailed financial information on the VKTX Financials page.
VKTX Stock Draws Fresh Attention Ahead Of Earnings: Wall Street Sees Over 170% Upside As GLP-1 Race Burns Hot
Viking Therapeutics (VKTX) stock is gaining attention ahead of its Q1 earnings, with analysts projecting a 170% upside due to its late-stage obesity drug program in the competitive GLP-1 market. The company is expected to report continued development-stage losses, but investor focus remains on its Phase 3 Vanquish program. The GLP-1 market is intensifying with new entrants like Structure Therapeutics and Altimmune, while established players Lilly, Novo Nordisk, and Amazon are also expanding their presence.
EBITDA per share of Viking Therapeutics, Inc. – MUN:1VT
This article provides an overview of the EBITDA per share for Viking Therapeutics, Inc. (MUN:1VT) on the Munich Stock Exchange. It indicates that the market was closed at the time of publication and lists general financial information available on the TradingView platform for the company.
Assessing Viking Therapeutics (VKTX) Valuation After Strong Multi‑Year Share Price Gains
This article assesses Viking Therapeutics (VKTX) after significant share price gains, noting its current valuation score of 3 out of 6. A Discounted Cash Flow (DCF) analysis suggests the stock is undervalued, indicating an intrinsic value of $256.32 per share compared to its $35.20 close. The Price-to-Book (P/B) ratio, at 6.38x, is close to peers but above the industry average, with no specific "Fair Ratio" available to classify it as overvalued or undervalued by that metric.
Why is Viking Therapeutics Poised to Be the Next Star Weight-Loss Stock?
Viking Therapeutics (VKTX) is emerging as a strong contender in the lucrative weight-loss drug market, currently dominated by Eli Lilly and Novo Nordisk. With its injectable VK2735 in Phase III trials and an oral candidate set to enter Phase III, Viking is developing GLP-1 class drugs that have shown promising results and significant stock surges on positive news. The company aims to capture market share in a field projected to reach nearly $100 billion by 2030, presenting a solid investment opportunity if its clinical trials continue to be successful.
Viking Therapeutics, Inc. (VKTX) exceeds market returns: Some facts to consider
This article from MSN discusses Viking Therapeutics, Inc. (VKTX) and its recent market performance, noting that its returns have surpassed the overall market. It prompts readers to consider key facts regarding this outperformance.
Viking Therapeutics (VKTX) to Release Earnings on Wednesday
Viking Therapeutics (VKTX) is scheduled to release its Q1 2026 earnings on Wednesday, April 22nd, after market close, with analysts projecting an EPS of ($1.01). The company missed previous quarterly estimates, reporting ($1.38) versus an estimated ($0.89). Despite this, Wall Street holds a "Moderate Buy" consensus with an average price target of $94.22, and recent insider and institutional investments indicate continued interest in the stock.
VKTX stock rises after-hours: CNBC flags Viking as likely buyout target this year as big pharma hunts next GLP-1 winner
This article reports on Viking Therapeutics (VKTX) stock rising in after-hours trading. CNBC has identified Viking as a potential buyout target for pharmaceutical companies in 2026, as big pharma seeks to acquire the next successful GLP-1 drug. The interest is driven by the race to find new and effective treatments in the booming GLP-1 market.
Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?
The article discusses whether Viking Therapeutics (VKTX) is a good investment based on Wall Street analyst recommendations. While the average brokerage recommendation (ABR) for VKTX is a "Buy" (1.33), the article cautions against relying solely on these recommendations due to inherent biases. It suggests using the Zacks Rank, which is based on earnings estimate revisions and has a proven track record, as a more reliable indicator for investment decisions.
Viking Therapeutics rises after Q4 updates on obesity therapy
Viking Therapeutics' stock saw a rise following its Q4 earnings call where the company provided updates on its obesity therapy program. Investors reacted positively to the communicated progress and future outlook for the weight loss treatment. The specific details of the updates were not fully disclosed in this snippet, but the market response indicates favorable news regarding the therapy.
